Last reviewed · How we verify
NCT03822494: CK-DESPOT
CyberKnife Dose Escalation Prostate Cancer Trial
NA trial testing CyberKnife SBRT in Prostate Cancer in 100 participants. Participants enrolled and being followed up; not accepting new ones.
21 June 2023
Quick facts
| Lead sponsor | Crozer-Keystone Health System |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 12 July 2018 |
| Primary completion | 21 June 2023 |
| Estimated completion | 12 July 2028 |
| Sites | 1 location across United States |
Drugs / interventions tested
- CyberKnife SBRT
Conditions studied
- Prostate Cancer — all drugs for Prostate Cancer →
- Prostate Adenocarcinoma — all drugs for Prostate Adenocarcinoma →
- Prostate Neoplasm — all drugs for Prostate Neoplasm →
Sponsor
Crozer-Keystone Health System
Who can join
18 and older, male only, with Prostate Cancer or Prostate Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Stereotactic body radiation therapy (SBRT) has been employed in the treatment of prostate cancer. Multiple single institution experiences suggest high biochemical control rates with acceptable toxicity in low risk prostate cancer but efficacy data in unfavorable type prostate cancer is less convincing. CyberKnife-SBRT (CK-SBRT) can be used to escalate radiation dose delivery to the prostate while sparing normal tissue.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Stereotactic Body Radiotherapy for Prostate Cancer.
Parikh NR, Kishan AU. · · 2020 · cited 12× · PMID 32500805 · DOI 10.1177/1557988320927241
Verify or expand the search:
- PubMed search for NCT03822494
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostate Cancer
Currently open trials in the same condition.
- NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
- NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
- NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
- NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
- NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting
Other Crozer-Keystone Health System trials
Trials by the same sponsor.
- NCT03734471 — Reactor Thoracostomy · Phase 3 · unknown
- NCT03825510 — Immunotherapy SBRT Sensitization of the Programmed Death-1 (PD-1) Effect · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03822494 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Crozer-Keystone Health System
- Last refreshed: 21 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03822494.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing